<DOC>
	<DOCNO>NCT00734071</DOCNO>
	<brief_summary>The purpose study determine safety efficacy vortioxetine , daily ( QD ) , treat Generalized Anxiety Disorder .</brief_summary>
	<brief_title>An Efficacy Safety Study Vortioxetine ( Lu AA21004 ) Treating Generalized Anxiety Disorder</brief_title>
	<detailed_description>The drug test study call Vortioxetine . Vortioxetine test treat anxiety adult general anxiety disorder ( GAD ) . This study look GAD relief people take vortioxetine . The study enrol 304 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Vortioxetine 5 mg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study . This multi-center trial conduct United States . The overall time participate study 13 week . Participants make 7 visit clinic , contact telephone 4 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Has primary diagnosis Generalized Anxiety Disorder accord Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR® ) criterion . Has Hamilton Anxiety Scale total score great equal 20 Screening Baseline . Has Hamilton Anxiety Scale score great equal 2 Item 1 ( anxious mood ) Item 2 ( tension ) Screening Baseline . Has MontgomeryÅsberg Depression Rating Scale total score less equal 16 Screening Baseline . Has 1 following : Any current psychiatric disorder Generalized Anxiety Disorder define DSMIVTR ( assess Mini International Neuropsychiatric Interview [ MINI ] ) . Current past history : manic hypomanic episode , schizophrenia psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Any substance disorder ( except nicotine caffeine ) within previous 6 month define DSMIVTR® subject must negative urine drug screen prior Baseline . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc. ) . Any Axis II disorder might compromise study . Is take excluded medication . Has significant risk suicide accord investigator 's opinion score great equal 5 Item 10 ( suicidal thought ) MontgomeryÅsberg Depression Rating Scale make suicide attempt previous 6 month . Has previously fail respond adequate treatment selective serotonin reuptake inhibitor and/or serotoninnorepinephrine reuptake inhibitor . Has receive electroconvulsive therapy within 6 month prior Screening . Is currently receive formal cognitive behavioral therapy , systematic psychotherapy , plan initiate therapy study . Has clinically significant unstable illness . Has alanine aminotransferase , aspartate aminotransferase , total bilirubin level great 1.5 time upper limit normal . Has serum creatinine great 1.5 time upper limit normal . Has previous history cancer remission le 5 year . Has thyroid stimulate hormone value outside normal range Screening deem clinically significant investigator . Has abnormal electrocardiogram .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>Mood Disorder</keyword>
	<keyword>Affective Disorder</keyword>
	<keyword>Anxiety Disorder</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>